Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 518 participants.

Also called NCT02926950

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 518 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02926950
  • EudraCT 2016-001800-49
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Hungary, Slovakia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02926950. Randomized; double masking; primary purpose treatment. Start 2016-11 (actual); primary completion 2019-02-26 (actual). Results posted on 2021-05-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sotagliflozin (SAR439954)
Intervention (Drug)
Placebo
Intervention (Drug)
Metformin
Lead sponsor
Lexicon Pharmaceuticals (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02926950
Content hash
f4ce78dd9bf78f0be741c2771ffedffc83c69e3e1b20a6a7429a23b7f4cfb345